{"id":745634,"date":"2018-11-12T06:55:00","date_gmt":"2018-11-12T06:55:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\/"},"modified":"2025-11-07T01:26:53","modified_gmt":"2025-11-07T06:26:53","slug":"fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\/","title":{"rendered":"FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review"},"content":{"rendered":"<p class=\"bwalignc\">       Approval Would Expand Use of AstraZeneca and Merck\u2019s LYNPARZA to        These Patients in the First-Line Setting Following Platinum-Based        Chemotherapy     <\/p>\n<p class=\"bwalignc\">       First U.S. Regulatory Submission Acceptance for a PARP Inhibitor as a        First-Line Maintenance Treatment for Certain Patients with Advanced        Ovarian Cancer     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States<br \/>\n      and Canada, today announced that the U.S. Food and Drug Administration<br \/>\n      (FDA) has accepted a supplemental New Drug Application (sNDA) for<br \/>\n      priority review for the approval of LYNPARZA tablets as a maintenance<br \/>\n      treatment in patients with newly-diagnosed, <i>BRCA<\/i>-mutated (<i>BRCA<\/i>m)<br \/>\n      advanced ovarian cancer who were in complete or partial response<br \/>\n      following first-line standard platinum-based chemotherapy. A<br \/>\n      Prescription Drug User Fee Act (PDUFA) date is set for the first quarter<br \/>\n      of 2019.\n    <\/p>\n<p>\n      This is the first U.S. regulatory submission acceptance for a poly<br \/>\n      ADP-ribose polymerase (PARP) inhibitor in the first-line maintenance<br \/>\n      setting for advanced ovarian cancer, and, if approved, will be the<br \/>\n      fourth indication for LYNPARZA in the U.S.\n    <\/p>\n<p>\n      This submission was based on positive results from the pivotal Phase 3<br \/>\n      SOLO-1 trial. The trial showed a statistically-significant and<br \/>\n      clinically-meaningful improvement in progression-free survival (PFS) for<br \/>\n      LYNPARZA compared to placebo, reducing the risk of disease progression<br \/>\n      or death by 70 percent in patients with newly-diagnosed, <i>BRCA<\/i>m<br \/>\n      advanced ovarian cancer who were in complete or partial response to<br \/>\n      platinum-based chemotherapy (HR=0.30 [95% CI 0.23-0.41]; p&lt;0.001). With<br \/>\n      a median 41 months of follow-up, the median PFS for patients treated<br \/>\n      with LYNPARZA (n=260) was not reached compared to 13.8 months for<br \/>\n      patients treated with placebo (n=131). Sixty percent of patients<br \/>\n      receiving LYNPARZA remained progression-free at 36 months, compared to<br \/>\n      27 percent of patients in the placebo arm. These data were recently<br \/>\n      presented for the first time at the ESMO 2018 Congress (European Society<br \/>\n      for Medical Oncology) and published online in the <i>New England Journal<br \/>\n      of Medicine<\/i>.\n    <\/p>\n<p>\n      LYNPARZA is a first-in-class PARP inhibitor approved in the U.S. since<br \/>\n      2014. LYNPARZA has a broad clinical development program and AstraZeneca<br \/>\n      and Merck are working together to deliver LYNPARZA as quickly as<br \/>\n      possible to more patients across multiple cancer types.\n    <\/p>\n<p>\n      <b>Important Safety Information<\/b>\n    <\/p>\n<p>\n      <b>Contraindications<\/b>\n    <\/p>\n<p>\n      There are no contraindications for LYNPARZA.\n    <\/p>\n<p>\n      <b>Warnings and Precautions<\/b>\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML)<\/b>:<br \/>\n      Occurred in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the<br \/>\n      majority of events had a fatal outcome. The duration of therapy in<br \/>\n      patients who developed secondary MDS\/AML varied from &lt;6 months to &gt;2<br \/>\n      years. All of these patients had previous chemotherapy with platinum<br \/>\n      agents and\/or other DNA-damaging agents, including radiotherapy, and<br \/>\n      some also had a history of more than one primary malignancy or of bone<br \/>\n      marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood count for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA and monitor blood count<br \/>\n      weekly until recovery.\n    <\/p>\n<p>\n      If the levels have not recovered to Grade 1 or less after 4 weeks, refer<br \/>\n      the patient to a hematologist for further investigations, including bone<br \/>\n      marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA<br \/>\n      if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis<\/b>: Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt LYNPARZA treatment and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity:<\/b> Based on its mechanism of action and<br \/>\n      findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is<br \/>\n      recommended for females of reproductive potential prior to initiating<br \/>\n      treatment.\n    <\/p>\n<p>\n      <i>Females<\/i>\n    <\/p>\n<p>\n      Advise females of reproductive potential of the potential risk to a<br \/>\n      fetus and to use effective contraception during treatment and for 6<br \/>\n      months following the last dose.\n    <\/p>\n<p>\n      <i>Males<\/i>\n    <\/p>\n<p>\n      Advise male patients with female partners of reproductive potential or<br \/>\n      who are pregnant to use effective contraception during treatment and for<br \/>\n      3 months following the last dose of LYNPARZA and to not donate sperm<br \/>\n      during this time.\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Maintenance Setting<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA in the maintenance setting for SOLO-2:<br \/>\n      nausea (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting<br \/>\n      (37%), nasopharyngitis\/upper respiratory tract infection (URI)\/influenza<br \/>\n      (36%), diarrhea (33%), arthralgia\/myalgia (30%), dysgeusia (27%),<br \/>\n      headache (26%), decreased appetite (22%), and stomatitis (20%).\n    <\/p>\n<p>\n      Study 19: nausea (71%), fatigue (including asthenia) (63%), vomiting<br \/>\n      (35%), diarrhea (28%), anemia (23%), respiratory tract infection (22%),<br \/>\n      constipation (22%), headache (21%), and decreased appetite (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the maintenance setting (SOLO-2\/Study 19)<br \/>\n      were: increase in mean corpuscular volume (89%\/82%), decrease in<br \/>\n      hemoglobin (83%\/82%), decrease in leukocytes (69%\/58%), decrease in<br \/>\n      lymphocytes (67%\/52%), decrease in absolute neutrophil count (51%\/47%),<br \/>\n      increase in serum creatinine (44%\/45%), and decrease in platelets<br \/>\n      (42%\/36%).\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Advanced g<i>BRCA<\/i>m Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA for advanced g<i>BRCA<\/i>m ovarian cancer<br \/>\n      after 3 or more lines of chemotherapy (pooled from 6 studies) were:<br \/>\n      fatigue (including asthenia) (66%), nausea (64%), vomiting (43%), anemia<br \/>\n      (34%), diarrhea (31%), nasopharyngitis\/upper respiratory tract infection<br \/>\n      (URI) (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%),<br \/>\n      and arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for advanced g<i>BRCA<\/i>m ovarian cancer<br \/>\n      (pooled from 6 studies) were: decrease in hemoglobin (90%), increase in<br \/>\n      mean corpuscular volume (57%), decrease in lymphocytes (56%), increase<br \/>\n      in serum creatinine (30%), decrease in platelets (30%), and decrease in<br \/>\n      absolute neutrophil count (25%).\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014g<i>BRCA<\/i>m, HER2-Negative Breast Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      OlympiAD were: nausea (58%), anemia (40%), fatigue (including asthenia)<br \/>\n      (37%), vomiting (30%), neutropenia (27%), respiratory tract infection<br \/>\n      (27%), leukopenia (25%), diarrhea (21%), and headache (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in &gt;25% of patients in<br \/>\n      OlympiAD were: decrease in hemoglobin (82%), decrease in lymphocytes<br \/>\n      (73%), decrease in leukocytes (71%), increase in mean corpuscular volume<br \/>\n      (71%), decrease in absolute neutrophil count (46%), and decrease in<br \/>\n      platelets (33%).\n    <\/p>\n<p>\n      <b>Drug Interactions<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents: <\/b>Clinical studies of LYNPARZA in combination<br \/>\n      with other myelosuppressive anticancer agents, including DNA-damaging<br \/>\n      agents, indicate a potentiation and prolongation of myelosuppressive<br \/>\n      toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors: <\/b>Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be<br \/>\n      co-administered, reduce the dose of LYNPARZA. Advise patients to avoid<br \/>\n      grapefruit, grapefruit juice, Seville oranges, and Seville orange juice<br \/>\n      during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers: <\/b>Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA. If a moderate inducer cannot be avoided,<br \/>\n      there is a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>Use In Specific Populations<\/b>\n    <\/p>\n<p>\n      <b>Lactation: <\/b>No data are available regarding the presence of<br \/>\n      olaparib in human milk, its effects on the breastfed infant or on milk<br \/>\n      production. Because of the potential for serious adverse reactions in<br \/>\n      the breastfed infant, advise a lactating woman not to breastfeed during<br \/>\n      treatment with LYNPARZA and for 1 month after receiving the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use: <\/b>The safety and efficacy of LYNPARZA have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Hepatic Impairment: <\/b>No adjustment to the starting dose is<br \/>\n      required in patients with mild hepatic impairment (Child-Pugh<br \/>\n      classification A). There are no data in patients with moderate or severe<br \/>\n      hepatic impairment.\n    <\/p>\n<p>\n      <b>Renal Impairment: <\/b>No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment (CLcr=51-80 mL\/min). In patients<br \/>\n      with moderate renal impairment (CLcr=31-50 mL\/min), reduce the dose to<br \/>\n      200 mg twice daily. There are no data in patients with severe renal<br \/>\n      impairment or end-stage renal disease (CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>Indications<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with recurrent<br \/>\n      epithelial ovarian, fallopian tube, or primary peritoneal cancer, who<br \/>\n      are in complete or partial response to platinum-based chemotherapy.\n    <\/p>\n<p>\n      For the treatment of adult patients with deleterious or suspected<br \/>\n      deleterious germline <i>BRCA-<\/i>mutated (g<i>BRCA<\/i>m) advanced<br \/>\n      ovarian cancer who have been treated with 3 or more prior lines of<br \/>\n      chemotherapy. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      In patients with deleterious or suspected deleterious g<i>BRCA<\/i>m,<i> <\/i>human<br \/>\n      epidermal growth factor receptor 2 (HER2)-negative metastatic breast<br \/>\n      cancer who have previously been treated with chemotherapy in the<br \/>\n      neoadjuvant, adjuvant or metastatic setting. Patients with hormone<br \/>\n      receptor (HR)-positive breast cancer should have been treated with a<br \/>\n      prior endocrine therapy or be considered inappropriate for endocrine<br \/>\n      treatment. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Please see complete <\/b><br \/>\n<a href=\"https:\/\/www.azpicentral.com\/lynparza_tb\/lynparza_tb.pdf\" rel=\"nofollow\"><br \/>\n<b>Prescribing<br \/>\n      Information<\/b><br \/>\n<\/a><br \/>\n<b>, including Patient Information (Medication Guide).<\/b>\n    <\/p>\n<p>\n      <b>About the SOLO-1 Phase 3 Trial<\/b>\n    <\/p>\n<p>\n      SOLO-1 is a Phase 3, randomized, double-blind, placebo-controlled,<br \/>\n      multi-center trial to evaluate the efficacy and safety of LYNPARZA<br \/>\n      tablets (300 mg<i> <\/i>twice daily) as maintenance monotherapy compared<br \/>\n      with placebo in newly-diagnosed patients with <i>BRCA<\/i>-mutated<br \/>\n      advanced ovarian cancer following platinum-based chemotherapy. The trial<br \/>\n      randomized 391 patients with a deleterious or suspected deleterious <i>BRCA1<\/i><br \/>\n      or <i>BRCA2<\/i> mutation who were in clinical complete or partial<br \/>\n      response following platinum-based chemotherapy. Patients were randomized<br \/>\n      (2:1) to receive LYNPARZA or placebo for up to two years or until<br \/>\n      disease progression (at the investigator\u2019s discretion). The primary<br \/>\n      endpoint was investigator-assessed progression-free survival and key<br \/>\n      secondary endpoints included time to second disease progression or<br \/>\n      death, time to first subsequent treatment and overall survival.\n    <\/p>\n<p>\n      <b>About Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Approximately 20,000 women in the U.S. are diagnosed with ovarian cancer<br \/>\n      (including ovarian, fallopian tube and primary peritoneal cancers) each<br \/>\n      year. Among women in the U.S., it is the ninth most common cancer and<br \/>\n      the fifth leading cause of cancer death.\n    <\/p>\n<p>\n      The risk of developing ovarian cancer is increased in women with<br \/>\n      specific inherited genetic abnormalities, including <i>BRCA<\/i><br \/>\n      mutations.\n    <\/p>\n<p>\n      <b>About <i>BRCA<\/i> Mutations<\/b>\n    <\/p>\n<p>\n      <i>BRCA1<\/i> and <i>BRCA2<\/i> are human genes that produce proteins<br \/>\n      responsible for repairing damaged DNA and play an important role in<br \/>\n      maintaining the genetic stability of cells. When either of these genes<br \/>\n      is mutated, or altered, such that its protein product either is not made<br \/>\n      or does not function correctly, DNA damage may not be repaired properly,<br \/>\n      and cells become unstable. As a result, cells are more likely to develop<br \/>\n      additional genetic alterations that can lead to cancer.\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib)<\/b>\n    <\/p>\n<p>\n      LYNPARZA is the first-in-class PARP inhibitor and the first targeted<br \/>\n      treatment to potentially exploit DNA damage response (DDR) pathway<br \/>\n      deficiencies, such as&nbsp;<i>BRCA<\/i>&nbsp;mutations, to preferentially kill<br \/>\n      cancer cells. Specifically, <i>in vitro<\/i> studies have shown that<br \/>\n      LYNPARZA-induced cytotoxicity may involve inhibition of PARP enzymatic<br \/>\n      activity and increased formation of PARP-DNA complexes, resulting in DNA<br \/>\n      damage and cancer cell death.<sup> <\/sup>LYNPARZA is being tested in a<br \/>\n      range of DDR-deficient tumor types.\n    <\/p>\n<p>\n      LYNPARZA, which is being jointly developed and commercialized by<br \/>\n      AstraZeneca and Merck, has a broad and advanced clinical trial<br \/>\n      development program, and AstraZeneca and Merck are working together to<br \/>\n      deliver it as quickly as possible to more patients across multiple<br \/>\n      cancer types.\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      In July 2017, AstraZeneca and Merck, known as MSD outside the United<br \/>\n      States and Canada, announced a global strategic oncology collaboration<br \/>\n      to co-develop and co-commercialize LYNPARZA, the world\u2019s first PARP<br \/>\n      inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for<br \/>\n      multiple cancer types. Working together, the companies will develop<br \/>\n      LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as monotherapies. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/index.html\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/www.youtube.com\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20181112005124r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Michael Close,        267-305-1211<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Michael        DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for priority review for the approval of LYNPARZA tablets as a maintenance treatment in patients with newly-diagnosed, BRCA -mutated ( BRCA m) advanced ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy. A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2019. This is the first U.S. regulatory submission acceptance for a poly ADP-ribose polymerase (PARP) inhibitor in the first-line maintenance setting for advanced ovarian cancer, and, if approved, will be the fourth indication for LYNPARZA in the U.S. This submission was based on positive results from the pivotal Phase 3 SOLO-1 trial. The trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,138,289,56],"class_list":["post-745634","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review - Merck.com\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for priority review for the approval of LYNPARZA tablets as a maintenance treatment in patients with newly-diagnosed, BRCA -mutated ( BRCA m) advanced ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy. A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2019. This is the first U.S. regulatory submission acceptance for a poly ADP-ribose polymerase (PARP) inhibitor in the first-line maintenance setting for advanced ovarian cancer, and, if approved, will be the fourth indication for LYNPARZA in the U.S. This submission was based on positive results from the pivotal Phase 3 SOLO-1 trial. The trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\\\/\",\"name\":\"FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-11-12T06:55:00+00:00\",\"dateModified\":\"2025-11-07T06:26:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\/","og_locale":"en_US","og_type":"article","og_title":"FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review - Merck.com","og_description":"AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for priority review for the approval of LYNPARZA tablets as a maintenance treatment in patients with newly-diagnosed, BRCA -mutated ( BRCA m) advanced ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy. A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2019. This is the first U.S. regulatory submission acceptance for a poly ADP-ribose polymerase (PARP) inhibitor in the first-line maintenance setting for advanced ovarian cancer, and, if approved, will be the fourth indication for LYNPARZA in the U.S. This submission was based on positive results from the pivotal Phase 3 SOLO-1 trial. The trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:53+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\/","name":"FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-11-12T06:55:00+00:00","dateModified":"2025-11-07T06:26:53+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-accepts-regulatory-submission-for-lynparza-olaparib-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"ad65e6d8-7c99-45fa-bf70-3a1cc17f6d58","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/FDA-Accepts-Regulatory-Submission-for-LYNPARZA-olaparib-Maintenance-Therapy-in-Newly-Diagnosed-BRCA-Mutated-Advanced-Ovarian-Cancer-a-9L63S.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745634\/revisions"}],"predecessor-version":[{"id":3674990,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745634\/revisions\/3674990"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745634"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}